Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

IntroductionPhosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minimal...

Full description

Bibliographic Details
Main Authors: David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pediatrics
Subjects:
adverse effect
echocardiography
hemodynamic
pulmonary vasodilator
safety
tolerability
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1055131/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1055131/full

Similar Items